PRIA Logo™
115-hr-6478115th Congress

Biosimilars Competition Act of 2018

Sponsored By: Representative Sarbanes, John P. [D-MD-3]

Unknown

Summary

Biosimilars Competition Act of 2018 This bill amends the Public Health Service Act to require a biologic manufacturer and a biosimilar drug manufacturer to provide notification to the Department of Justice and the Federal Trade Commission regarding certain pharmaceutical agreements. The agreements requiring notice are those related to the manufacturer, marketing or sale of the biosimilar product or the reference product. Biosimilars are biological products approved by the Food and Drug Administration based on their similarity to an already-approved biological product.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Sarbanes, John P. [D-MD-3]

MD • D

Cosponsors

  • Rep. Johnson, Bill [R-OH-6]

    OH • R

    Sponsored 7/23/2018

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation